View Future GrowthPrecision Biosensor 과거 순이익 실적과거 기준 점검 0/6Precision Biosensor 의 수입은 연평균 -19.2%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 4.6%의 비율로 증가했습니다. 매출은 연평균 5.9%의 비율로 증가해 왔습니다.핵심 정보-19.16%순이익 성장률-15.92%주당순이익(EPS) 성장률Medical Equipment 산업 성장률22.66%매출 성장률5.88%자기자본이익률-18.23%순이익률-35.25%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).모든 업데이트 보기Recent updates공시 • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South KoreaNew Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).공시 • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.분석 기사 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.공시 • Mar 06Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea분석 기사 • Dec 16Precision Biosensor, Inc.'s (KOSDAQ:335810) Business Is Yet to Catch Up With Its Share PriceWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...분석 기사 • Sep 10Some Confidence Is Lacking In Precision Biosensor, Inc. (KOSDAQ:335810) As Shares Slide 30%Precision Biosensor, Inc. ( KOSDAQ:335810 ) shareholders that were waiting for something to happen have been dealt a...분석 기사 • Aug 26We Think Precision Biosensor (KOSDAQ:335810) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jul 02Subdued Growth No Barrier To Precision Biosensor, Inc.'s (KOSDAQ:335810) PriceWhen close to half the companies in the Medical Equipment industry in Korea have price-to-sales ratios (or "P/S") below...New Risk • May 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m).Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.공시 • Feb 07Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investorPrecision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029.Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).매출 및 비용 세부 내역Precision Biosensor가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A335810 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2622,336-7,8747,9992,29731 Dec 2519,926-10,0237,5462,58430 Sep 2519,737-7,8767,0112,82930 Jun 2519,361-8,9056,6633,06531 Mar 2519,588-7,6436,3233,45931 Dec 2419,134-7,3056,3033,58630 Sep 2418,215-8,0096,8433,70730 Jun 2417,135-6,8067,0383,54531 Mar 2418,103-5,8387,4123,35331 Dec 2320,391-4,4907,5293,19630 Sep 2320,570-4,2317,6112,99530 Jun 2320,885-5,0567,5123,03731 Mar 2319,787-7,0167,4612,84031 Dec 2220,458-6,8067,6012,61130 Sep 2222,808-6,2517,4952,46330 Jun 2223,500-4,7337,8141,75231 Mar 2221,233-3,3087,7421,50931 Dec 2115,887-4,1526,3051,95830 Sep 2114,255-2,2505,4142,08430 Jun 2111,111-2,2154,9672,08431 Mar 219,447-4,9474,1582,24031 Dec 208,685-4,9533,9072,04530 Sep 205,292-6,2213,6971,93431 Dec 196,205-4053,2171,66531 Dec 184,588-4,0402,6081,83131 Dec 174,406-2,4552,4021,67231 Dec 164,913-1,2942,5891,67031 Dec 151,387-1,4251,298578양질의 수익: A335810 은(는) 현재 수익성이 없습니다.이익 마진 증가: A335810는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A335810은 수익성이 없으며 지난 5년 동안 손실이 연평균 19.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A335810의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A335810은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(19.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A335810는 현재 수익성이 없으므로 자본 수익률이 음수(-18.23%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 17:26종가2026/05/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Precision Biosensor, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).
공시 • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
New Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).
공시 • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.
분석 기사 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).
Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
공시 • Mar 06Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
분석 기사 • Dec 16Precision Biosensor, Inc.'s (KOSDAQ:335810) Business Is Yet to Catch Up With Its Share PriceWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...
분석 기사 • Sep 10Some Confidence Is Lacking In Precision Biosensor, Inc. (KOSDAQ:335810) As Shares Slide 30%Precision Biosensor, Inc. ( KOSDAQ:335810 ) shareholders that were waiting for something to happen have been dealt a...
분석 기사 • Aug 26We Think Precision Biosensor (KOSDAQ:335810) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Jul 02Subdued Growth No Barrier To Precision Biosensor, Inc.'s (KOSDAQ:335810) PriceWhen close to half the companies in the Medical Equipment industry in Korea have price-to-sales ratios (or "P/S") below...
New Risk • May 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m).
Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
공시 • Feb 07Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investorPrecision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029.
Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).